ストックスクリーナーアプリを入手
5.21
0.95%
-0.05
前日終値:
$5.26
開ける：
$5.27
24時間の取引高:
1.13M
Relative Volume:
0.83
時価総額：
$142.72M
収益：
$675.00K
当期純損益:
$-26.62M
株価収益率:
-3.3178
EPS:
-1.5703
ネットキャッシュフロー:
$-31.34M
1週間 パフォーマンス:
-9.08%
1か月 パフォーマンス:
-32.25%
6か月 パフォーマンス:
-15.70%
1年 パフォーマンス:
-0.76%
1日の値動き範囲:
$5.0606
$5.36
1週間の範囲:
$5.01
$5.93
52週間の値動き範囲:
$3.71
$8.74
Unicycive Therapeutics Inc Stock (UNCY) Company Profile
名前
Unicycive Therapeutics Inc
セクター
電話
650-384-0642
住所
1975 W. EL CAMINO REAL, SUITE 204, MOUNTAIN VIEW
Compare UNCY vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
UNCY
Unicycive Therapeutics Inc
|
5.21 | 142.72M | 675.00K | -26.62M | -31.34M | -1.5703 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Unicycive Therapeutics Inc Stock (UNCY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-21 | 開始されました | Guggenheim | Buy |
| 2024-04-04 | 開始されました | Piper Sandler | Overweight |
Unicycive Therapeutics Inc (UNCY) 最新ニュース
UNCY INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Unicycive Therapeutics, Inc. - GlobeNewswire
UNCY Stock Clocks Worst Day In A Year — Analysts Keep Buy Ratings Despite ‘5-12 Month Delay’ In Drug Approval - Stocktwits
Millennium-affiliated holders disclose 271,456 shares in Unicycive Therapeutics (UNCY) - Stock Titan
ALHC ALERT: Block & Leviton Investigating Alignment Healthcare, Inc. For Possible Securities Fraud; Investors Should Contact Block & Leviton to Learn More - GlobeNewswire Inc.
Securities Fraud Investigation Into Unicycive Therapeutics, Inc. (UNCY) Announced – Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz - The AI Journal
Weekly Recap: FDA acceptance, June 29 date and Brokers keep Buy ratings - TradingView
Price to book forward of Unicycive Therapeutics, Inc. – NASDAQ:UNCY - TradingView
Price to earnings forward of Unicycive Therapeutics, Inc. – NASDAQ:UNCY - TradingView
UNCYUnicycive Therapeutics Inc Short Interest - Finviz
Unicycive Therapeutics Reports Preliminary Q2 2026 Cash Position - The Globe and Mail
Bragar Eagel & Squire, P.C. is Investigating Unicycive - GlobeNewswire
Unicycive Therapeutics, Inc. Files Form 8-K for Key Event on July 2, 2026 – Company Details, NASDAQ Ticker, and Emerging Growth Status – Minichart - Minichart
Unicycive Therapeutics reports $61.4M cash balance as of June 30, 2026 - TradingView
Unicycive Therapeutics (UNCY) discloses $61.4M cash balance in preliminary Q2 2026 update - Stock Titan
$Unicycive Therapeutics (UNCY.US)$ FDA reject on the previous reject. See below. - Moomoo
UNCY INVESTIGATION ALERT: Investors Who Lost Money in Unicycive Therapeutics, Inc. Should Contact Block & Leviton - marketscreener.com
UNICYCIVE THERAPEUTICS, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud - Business Wire
Form 144 Unicycive Therapeutics For: 1 July By Investing.com - Investing.com Nigeria
Unicycive Therapeutics (UNCY) Is Down 33.1% After FDA CRL Cites Third-Party Manufacturing Deficiencies - Yahoo Finance
Unicycive Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Unicycive plummets following second CRL for OLC for hyperphosphatemia - MSN
UNCY Maintained by Benchmark -- Price Target Lowered to $13.00 - GuruFocus
UNCY Maintained by Noble Capital Markets -- Price Target Lowered to $50 - GuruFocus
UNCY ALERT: Unicycive Therapeutics, Inc. Investigated for Securities Fraud by Block & ... - Caledonian Record
UNCY ALERT: Unicycive Therapeutics, Inc. Investigated for - GlobeNewswire
Benchmark cuts Unicycive Therapeutics price target on FDA setback - Investing.com UK
Why Is Unicycive Therapeutics Stock Falling Tuesday? - Sahm
Benchmark Co. Maintains Unicycive Therapeutics(UNCY.US) With Buy Rating, Cuts Target Price to $13 - Moomoo
Unicycive Therapeutics (NASDAQ:UNCY) Is In A Good Position To Deliver On Growth Plans - Moomoo
Unicycive Therapeutics: Second CRL Exposes Execution Risk Behind OLC Story (NASDAQ:UNCY) - Seeking Alpha
Benchmark cuts Unicycive Therapeutics price target on FDA setback By Investing.com - Investing.com South Africa
Powerful - Moomoo
Guggenheim Maintains Unicycive Therapeutics(UNCY.US) With Buy Rating, Maintains Target Price $37 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Unicycive Therapeutics stock tumbles on FDA rejection letter - Investing.com
Unicycive Therapeutics Receives FDA Complete Response Letter for Oxylanthanum Carbonate NDA - mydailyrecord.com
H.C. Wainwright Maintains Unicycive Therapeutics(UNCY.US) With Buy Rating, Cuts Target Price to $15 - Moomoo
Unicycive shares plunge after FDA issues complete response letter for kidney disease drug (UNCY) - MSN
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
UNCY Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
Law firm probes Unicycive Therapeutics after FD... - Pluang
Johnson Fistel Investigates Unicycive Therapeutics, Inc. (NASDAQ: UNCY) on Behalf of Investors - GlobeNewswire
Unicycive receives FDA rejection for kidney disease drug - Investing.com UK
$Unicycive Therapeutics (UNCY.US)$ - Moomoo
B. Riley Securities Maintains Unicycive Therapeutics(UNCY.US) With Buy Rating, Maintains Target Price $22 - Moomoo
Why is Unicycive Therapeutics stock collapsing today? By Investing.com - Investing.com Canada
Unicycive gets FDA CRL for OLC kidney drug application - grafa.com
UNCY Extends ATM Offering As Dilution Fears Hit The Chart - StocksToTrade
US FDA declines to approve Unicycive's kidney disease drug - Reuters
US Stocks Mixed; Home Prices Increase 1.1% In April - Benzinga
Unicycive slides as FDA delay, dilution weigh premarket - TechStock²
Unicycive Therapeutics Inc (UNCY) 財務データ
収益
当期純利益
現金流量
EPS
2.64%
大文字化:
|
ボリューム (24 時間):